| 4,037 | 66 | 2156 |
| 下载次数 | 被引频次 | 阅读次数 |
<正>从肿瘤的发生学上来说,肿瘤细胞是由正常细胞转变而来的,这种从"自己"到"非己"的过程往往会受到机体免疫系统的严密监视,被有效的免疫应答所清除。然而肿瘤细胞能够利用多种机制和途径抑制免疫细胞的活性,如阻断CD8+T细胞和自然杀伤细胞(natural killer cell,NK)对其识别和杀伤,甚至驯化免疫系统来促进其生长和转移,使肿瘤微环境中的免疫系统处于耐受状态,主要体现在肿瘤特
Abstract:[1]Joyce JA,Fearon DT.T cell exclusion,immune privilege,and the tumor microenvironment[J].Science,2015,348(6230):74-80.
[2]Couzin-Frankel J.Breakthrough of the year 2013.Cancer immunotherapy[J].Science,2013,342(6165):1432-1433.
[3]Drake CG,Lipson EJ,Brahmer JR.Breathing new life into immunotherapy:review of melanoma,lung and kidney cancer[J].Nat Rev Clin Oncol,2014,11(1):24-37.
[4]Ohaegbulam KC,Assal A,Lazar-Molnar E,et al.Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway[J].Trends Mol Med,2015,21(1):24-33.
[5]Perez-Gracia JL,Labiano S,Rodriguez-Ruiz ME,et al.Orchestrating immune check-point blockade for cancer immunotherapy in combinations[J].Curr Opin Immunol,2014,27:89-97.
[6]Quezada SA,Peggs KS.Exploiting CTLA-4,PD-1 and PDL1 to reactivate the host immune response against cancer[J].Br J Cancer,2013,108(8):1560-1565.
[7]Rosenberg SA,Restifo NP.Adoptive cell transfer as personalized immunotherapy for human cancer[J].Science,2015,348(6230):62-68.
[8]Gross G,Waks T,Eshhar Z.Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity[J].Proc Natl Acad Sci U S A,1989,86(24):10024-10028.
[9]Lee DW,Kochenderfer JN,Stetler-Stevenson M,et al.T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults:a phase 1 dose-escalation trial[J].Lancet,2015,385(9967):517-528.
[10]Gill S,Maus MV,Porter DL.Chimeric antigen receptor T cell therapy:25 years in the making[J].Blood Rev,2015.Epub ahead of print.
[11]Haso W,Lee DW,Shah NN,et al.Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia[J].Blood,2013,121(7):1165-1174.
[12]Porter DL,Levine BL,Kalos M,et al.Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia[J].N Engl J Med,2011,365(8):725-733.
[13]Morgan RA,Yang JC,Kitano M,et al.Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2[J].Mol Ther,2010,18(4):843-851.
[14]Kantoff PW,Higano CS,Shore ND,et al.Sipuleucel-T immunotherapy for castration-resistant prostate cancer[J].N Engl J Med,2010,363(5):411-422.
[15]Vansteenkiste J,Zielinski M,Linder A,et al.Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer:phaseⅡrandomized study results[J].J Clin Oncol,2013,31(19):2396-2403.
[16]Milani A,Sangiolo D,Aglietta M,et al.Recent advances in the development of breast cancer vaccines[J].Breast Cancer,2014,6:159-168.
[17]Coulie PG,van den Eynde BJ,van der Bruggen P,et al.Tumour antigens recognized by T lymphocytes:at the core of cancer immunotherapy[J].Nat Rev Cancer,2014,14(2):135-146.
[18]Chelius D,Ruf P,Gruber P,et al.Structural and functional characterization of the trifunctional antibody catumaxomab[J].MAbs,2010,2(3):309-319.
[19]Ghiringhelli F,Menard C,Puig PE,et al.Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+regulatory T cells and restores T and NK effector functions in end stage cancer patients[J].Cancer Immunol Immunother,2007,56(5):641-648.
[20]Kawai M,Kitade H,Mathieu C,et al.Inhibitory and stimulatory effects of cyclosporine A on the development of regulatory T cells in vivo[J].Transplantation,2005,79(9):1073-1077.
[21]Bass KK,Mastrangelo MJ.Immunopotentiation with lowdose cyclophosphamide in the active specific immunotherapy of cancer[J].Cancer Immunol Immunother,1998,47(1):1-12.
[22]Germano G,Frapolli R,Belgiovine C,et al.Role of macrophage targeting in the antitumor activity of trabectedin[J].Cancer Cell,2013,23(2):249-262.
[23]Annels NE,Shaw VE,Gabitass RF,et al.The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer[J].Cancer Immunol Immunother,2014,63(2):175-183.
[24]Mirza N,Fishman M,Fricke I,et al.All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients[J].Cancer Res,2006,66(18):9299-9307.
[25]Zolot RS,Basu S,Million RP.Antibody-drug conjugates[J].Nat Rev Drug Discov,2013,12(4):259-260.
基本信息:
DOI:10.13267/j.cnki.syzlzz.2016.01.003
中图分类号:R730.51
引用信息:
[1]肖鹏,曹雪涛,王青青.恶性肿瘤免疫治疗的现状及展望[J],2016,31(01):5-9.DOI:10.13267/j.cnki.syzlzz.2016.01.003.